FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083667265> ?p ?o ?g. }

• W3083667265 endingPage "1339" @default.
• W3083667265 startingPage "1330" @default.
• W3083667265 abstract "Non-small cell lung cancer (NSCLC) accounts for 80-90% of all lung cancer cases and is usually associated with a poor prognosis. However, targeted therapy with first and second generation tyrosine kinase inhibitors (TKIs) has so far improved progression-free survival of epidermal growth factor receptor (EGFR) mutant NSCLC patients. Osimertinib, a third generation EGFR TKI has recently shown improved overall survival of 6.8 months in previously untreated EGFR mutant NSCLC patients. We assessed the cost-effectiveness of osimertinib versus standard EGFR TKIs (gefitinib or erlotinib) as first-line treatment for advanced or metastatic EGFR mutant NSCLC patients in Singapore.A partitioned survival model with three health states (progression-free, progressive disease, and death) was developed from the Singapore healthcare payer perspective. Survival curves based on the overall trial population from the FLAURA trial were extrapolated beyond trial period over a 10-year time horizon to estimate the underlying progression-free survival and overall survival parametric distributions. Health state utilities were derived from the literature and direct costs were sourced from public healthcare institutions in Singapore. Deterministic and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties and assumptions on cost-effectiveness results.Compared with first or second generation TKI, osimertinib had a base-case incremental cost-effectiveness ratio (ICER) of SG$418,839 (US$304,277) per quality-adjusted life year gained. One-way sensitivity analysis showed the ICER was most sensitive to time horizon and variations in progression-free utility values. Scenario analyses showed that a 50% reduction in the cost of osimertinib was still associated with a high ICER that was unlikely to be deemed cost effective.Osimertinib is not cost effective as a first-line treatment compared to standard EGFR TKIs in advanced EGFR mutant NSCLC patients in Singapore. The findings from our evaluation, alongside other considerations including the lack of survival benefit in the Asian subgroup of the FLAURA trial, will be useful to inform policy makers on funding decisions for NSCLC treatments in Singapore." @default.
• W3083667265 created "2020-09-11" @default.
• W3083667265 creator A5007239888 @default.
• W3083667265 creator A5015796890 @default.
• W3083667265 creator A5035273217 @default.
• W3083667265 creator A5070131987 @default.
• W3083667265 date "2020-09-21" @default.
• W3083667265 modified "2023-10-18" @default.
• W3083667265 title "Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore" @default.
• W3083667265 cites W1982967337 @default.
• W3083667265 cites W1984886683 @default.
• W3083667265 cites W2088540000 @default.
• W3083667265 cites W2128473443 @default.
• W3083667265 cites W2129590156 @default.
• W3083667265 cites W2130256619 @default.
• W3083667265 cites W2130629599 @default.
• W3083667265 cites W2154149901 @default.
• W3083667265 cites W2296800272 @default.
• W3083667265 cites W2536396512 @default.
• W3083667265 cites W2560717039 @default.
• W3083667265 cites W2591118779 @default.
• W3083667265 cites W2607954371 @default.
• W3083667265 cites W2621102834 @default.
• W3083667265 cites W2753207486 @default.
• W3083667265 cites W2770828094 @default.
• W3083667265 cites W2795300271 @default.
• W3083667265 cites W2805264144 @default.
• W3083667265 cites W2888952267 @default.
• W3083667265 cites W2893040167 @default.
• W3083667265 cites W2895926103 @default.
• W3083667265 cites W2911174524 @default.
• W3083667265 cites W2990041408 @default.
• W3083667265 cites W4210992155 @default.
• W3083667265 cites W4292343002 @default.
• W3083667265 doi "https://doi.org/10.1080/13696998.2020.1819822" @default.
• W3083667265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32886557" @default.
• W3083667265 hasPublicationYear "2020" @default.
• W3083667265 type Work @default.
• W3083667265 sameAs 3083667265 @default.
• W3083667265 citedByCount "8" @default.
• W3083667265 countsByYear W30836672652021 @default.
• W3083667265 countsByYear W30836672652022 @default.
• W3083667265 countsByYear W30836672652023 @default.
• W3083667265 crossrefType "journal-article" @default.
• W3083667265 hasAuthorship W3083667265A5007239888 @default.
• W3083667265 hasAuthorship W3083667265A5015796890 @default.
• W3083667265 hasAuthorship W3083667265A5035273217 @default.
• W3083667265 hasAuthorship W3083667265A5070131987 @default.
• W3083667265 hasBestOaLocation W30836672651 @default.
• W3083667265 hasConcept C112930515 @default.
• W3083667265 hasConcept C121608353 @default.
• W3083667265 hasConcept C126322002 @default.
• W3083667265 hasConcept C143998085 @default.
• W3083667265 hasConcept C2776256026 @default.
• W3083667265 hasConcept C2776694085 @default.
• W3083667265 hasConcept C2777626846 @default.
• W3083667265 hasConcept C2778087573 @default.
• W3083667265 hasConcept C2779438470 @default.
• W3083667265 hasConcept C2780580887 @default.
• W3083667265 hasConcept C2780739268 @default.
• W3083667265 hasConcept C2908647359 @default.
• W3083667265 hasConcept C3019080777 @default.
• W3083667265 hasConcept C71924100 @default.
• W3083667265 hasConcept C99454951 @default.
• W3083667265 hasConceptScore W3083667265C112930515 @default.
• W3083667265 hasConceptScore W3083667265C121608353 @default.
• W3083667265 hasConceptScore W3083667265C126322002 @default.
• W3083667265 hasConceptScore W3083667265C143998085 @default.
• W3083667265 hasConceptScore W3083667265C2776256026 @default.
• W3083667265 hasConceptScore W3083667265C2776694085 @default.
• W3083667265 hasConceptScore W3083667265C2777626846 @default.
• W3083667265 hasConceptScore W3083667265C2778087573 @default.
• W3083667265 hasConceptScore W3083667265C2779438470 @default.
• W3083667265 hasConceptScore W3083667265C2780580887 @default.
• W3083667265 hasConceptScore W3083667265C2780739268 @default.
• W3083667265 hasConceptScore W3083667265C2908647359 @default.
• W3083667265 hasConceptScore W3083667265C3019080777 @default.
• W3083667265 hasConceptScore W3083667265C71924100 @default.
• W3083667265 hasConceptScore W3083667265C99454951 @default.
• W3083667265 hasIssue "11" @default.
• W3083667265 hasLocation W30836672651 @default.
• W3083667265 hasLocation W30836672652 @default.
• W3083667265 hasLocation W30836672653 @default.
• W3083667265 hasOpenAccess W3083667265 @default.
• W3083667265 hasPrimaryLocation W30836672651 @default.
• W3083667265 hasRelatedWork W1991551364 @default.
• W3083667265 hasRelatedWork W2015104488 @default.
• W3083667265 hasRelatedWork W2134157108 @default.
• W3083667265 hasRelatedWork W2184487997 @default.
• W3083667265 hasRelatedWork W2254126652 @default.
• W3083667265 hasRelatedWork W2280113021 @default.
• W3083667265 hasRelatedWork W2348666640 @default.
• W3083667265 hasRelatedWork W2363852307 @default.
• W3083667265 hasRelatedWork W2418692205 @default.
• W3083667265 hasRelatedWork W3147989365 @default.
• W3083667265 hasVolume "23" @default.
• W3083667265 isParatext "false" @default.
• W3083667265 isRetracted "false" @default.

• next